**9. Conclusion**

The appearance of clinical changes on fundus examination of patients with macular dystrophies is synonymous with the already established damage of a certain level with consequent visual morbidity. Until the present date, OCTA has proven its efficacy in imaging macular dystrophies and identifying the morphological alteration in the vascular layers of the ocular fundus associated with different disease stages. Moreover, SS-OCTA is an essential imaging tool whenever FFA and SS-OCT reveal inconclusive results in the advent of CNV development secondary to vitelliform macular dystrophy. The future of OCTA in imaging macular dystrophies lies in its potential for screening target population and identifying patients at incipient disease stages well in advance of visible clinical changes by depicting specific OCTA pattern or OCTA *signature* that is diagnostic for a particular macular dystrophy. The objective is to identify patients who would be best candidates for the ongoing trials on gene therapy and stem cell transplantation before irreversible visual dysfunction sets in.
